- Home
- NRSN vs INAB Comparison
NRSN vs INAB Comparison
Compare NRSN & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- INAB
- Stock Information
- Founded
- NRSN 2017
- INAB 2016
- Country
- NRSN Israel
- INAB United States
- Employees
- NRSN N/A
- INAB N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- NRSN Health Care
- INAB Health Care
- Exchange
- NRSN Nasdaq
- INAB Nasdaq
- Market Cap
- NRSN 17.8M
- INAB 18.8M
- IPO Year
- NRSN 2021
- INAB 2021
- Fundamental
- Price
- NRSN $1.12
- INAB $0.23
- Analyst Decision
- NRSN Hold
- INAB Strong Buy
- Analyst Count
- NRSN 1
- INAB 3
- Target Price
- NRSN N/A
- INAB $5.57
- AVG Volume (30 Days)
- NRSN 129.6K
- INAB 3.1M
- Earning Date
- NRSN 04-04-2025
- INAB 05-08-2025
- Dividend Yield
- NRSN N/A
- INAB N/A
- EPS Growth
- NRSN N/A
- INAB N/A
- EPS
- NRSN N/A
- INAB N/A
- Revenue
- NRSN N/A
- INAB N/A
- Revenue This Year
- NRSN N/A
- INAB N/A
- Revenue Next Year
- NRSN N/A
- INAB N/A
- P/E Ratio
- NRSN N/A
- INAB N/A
- Revenue Growth
- NRSN N/A
- INAB N/A
- 52 Week Low
- NRSN $0.51
- INAB $0.22
- 52 Week High
- NRSN $2.25
- INAB $1.74
- Technical
- Relative Strength Index (RSI)
- NRSN 51.47
- INAB 38.50
- Support Level
- NRSN $0.96
- INAB $0.23
- Resistance Level
- NRSN $1.17
- INAB $0.25
- Average True Range (ATR)
- NRSN 0.08
- INAB 0.02
- MACD
- NRSN 0.00
- INAB -0.00
- Stochastic Oscillator
- NRSN 66.24
- INAB 11.40
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.